Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder.
J Affect Disord
; 332: 105-114, 2023 07 01.
Article
in En
| MEDLINE
| ID: mdl-36958488
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Depressive Disorder, Major
/
Serotonin and Noradrenaline Reuptake Inhibitors
Type of study:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Affect Disord
Year:
2023
Document type:
Article
Affiliation country:
Austria
Country of publication:
Netherlands